Table 1.
Baseline characteristics of participants relative to development of major renal function decline during the 7-year follow-up period.
| Overall | Men | Women | p Value | |
|---|---|---|---|---|
| n | 3712 | 2008 | 1704 | |
| Age (years) | 40.55 ± 10.74 | 40.82 ± 9.95 | 40.23 ± 11.58 | 0.102 |
| BMI (kg/m2) | 23.60 ± 3.61 | 24.72 ± 3.07 | 22.28 ± 3.74 | <0.001 |
| SBP (mmHg) | 121.07 ± 17.05 | 124.88 ± 16.64 | 116.59 ± 16.44 | <0.001 |
| DBP (mmHg) | 77.31 ± 11.88 | 80.80 ± 11.60 | 73.20 ± 10.86 | <0.001 |
| TC (mmol/L) | 4.62 ± 0.88 | 4.68 ± 0.87 | 4.55 ± 0.89 | <0.001 |
| TG (mmol/L) | 1.05 (0.72–1.61) | 1.31 (0.92–1.90) | 0.81 (0.61–1.16) | <0.001 |
| HDL-C (mmol/L) | 1.34 ± 0.32 | 1.21 ± 0.26 | 1.50 ± 0.31 | <0.001 |
| LDL-C (mmol/L) | 2.77 ± 0.75 | 2.89 ± 0.73 | 2.63 ± 0.74 | <0.001 |
| AIP | −0.07 ± 0.32 | 0.06 ± 0.29 | −0.23 ± 0.27 | <0.001 |
| FPG (mmol/L) | 5.10 ± 0.52 | 5.15 ± 0.53 | 5.05 ± 0.50 | <0.001 |
| UA (mg/dL) | 310.88 ± 84.32 | 362.25 ± 70.54 | 250.34 ± 53.40 | <0.001 |
| SCr (μmol/L) | 65.62 ± 12.68 | 74.88 ± 8.10 | 54.71 ± 7.28 | <0.001 |
| eGFR (mL/min/1.73 m2) | 110.20 ± 10.79 | 107.81 ± 9.53 | 113.01 ± 11.48 | <0.001 |
| Hypertension, n (%) | 785 | 563 (28.0) | 222 (13.0) | <0.001 |
Data are mean ± SD, median (IQR) or percentage.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; AIP: atherogenic index of plasma; FBG: fasting plasma glucose; UA: uric acid; SCr: serum creatinine; eGFR: estimated glomerular filtration rate.